N anotechnology holds tremendous potential for early detection, accurate diagnosis, and personalized treatment of cancer.
N anotechnology holds tremendous potential for early detection, accurate diagnosis, and personalized treatment of cancer. 1, 2 For imaging applications, fluorescence imaging is inexpensive and convenient and hence has been widely used in preclinical research, with the best example being quantum dots (QDs). 3À6 Specific targeting of tumor vasculature and tumor cells in vivo has been achieved with various QD-based conjugates. 7À12 However, two major roadblocks for potential widespread application and clinical translation of QDs are their potential toxicity and inefficient delivery. Zinc oxide (ZnO) is well-recognized as a biocompatible multifunctional material with exceptional semiconducting, optical, and piezoelectric properties. 13 It exhibits the most diverse family of nanostructures that can be employed for different applications such as lightemitting diodes, lasers, sensors, actuators, transducers, nanogenerators, etc.
13À18 ZnO is also a wide band gap semiconductor (3.37 eV) with high exciton binding energy (60 meV), which leads to efficient excitonic blue and near-UV emission. 19 One of the most important features of ZnO nanomaterials is low toxicity and biodegradability. Zn 2+ is an indispensable trace element for adults; 9.5 and 7.0 mg of Zn 2+ per day are needed for adult men and women, respectively. Chemically, the surface of ZnO is mostly terminated by ÀOH groups, which can be readily functionalized by various surface decorating molecules.
20À22
ZnO can slowly dissolve in both acidic (e.g., in tumor cells/ microenvironment) and strong basic conditions if the surface is in direct contact with the solution. 23 These properties make ZnO nanomaterials excellent candidates as biocompatible and biodegradable nanoplatforms for biomedical applications such as DNA delivery, 24 ,25 magnetic resonance imaging (MRI), 26 and sensing. 27À29 For optical imaging applications, ZnO nanomaterials (e.g., nanorods, nanosheets, nanocrystals) have been employed for sum-frequency generation and fluorescence imaging of cells.
30À34
In addition, ZnO-based QDs have been reported for fluorescence or dual-modality MRI/fluorescence imaging.
25,35À37
The major obstacles for biomedical applications of ZnO nanomaterials include low-intensity and short-wavelength luminescence of ZnO, limited capability in the size control of ZnO nanostructures (<200 nm is preferred for in vivo investigations), and sharpness/stiffness of ceramic-based nanostructures (rigid and sharp tips/edges should be avoided to prevent cell/tissue damage). In this study, we synthesized green fluorescent ZnO nanowires (NWs) which overcome these obstacles and demonstrated the proof-of-principle that ZnO NWs can be specifically targeted to cell surface receptors in vitro, which opened up new avenues of future research in tumor-targeted drug delivery. The one-dimensional shape of a ZnO NW is highly desirable for efficient tumor targeting since such morphology can readily take advantage of the polyvalency effect. 38 With future in vivo investigations in mind, we chose integrin R v β 3 as the target in this study. Integrin R v β 3 , which binds to arginine-glycine-aspartic acid (RGD)-containing peptides/ proteins, 39, 40 is a key protein involved in tumor angiogenesis and metastasis.
41À43 It is overexpressed in a variety of solid tumor types (e.g., melanoma, late stage glioblastoma, breast, prostate, and ovarian cancers) 44 but is not readily detectable in resting endothelial cells or most normal organs, which makes it a universally applicable target for molecular imaging and therapy of cancer. Most importantly, since efficient extravasation is the key hurdle for most nanomaterial-based tumor targeting and
ABSTRACT: Herein we demonstrate that intrinsically fluorescent zinc oxide (ZnO) nanowires (NWs) can be adopted for molecularly targeted imaging of cancer cells, after they are functionalized to render water solubility, biocompatibility, and low cellular toxicity. Optical imaging of integrin R v β 3 on U87MG human glioblastoma cells was achieved with RGD peptide-conjugated green fluorescent ZnO NWs, which opened up new avenues of research for investigating ZnO NW-based agents in tumor vasculature-targeted molecular imaging and drug delivery.
KEYWORDS: Zinc oxide (ZnO), nanowire (NW), fluorescence, cancer, molecular imaging, integrin R v β 3 Nano Letters LETTER imaging, the fact that integrin R v β 3 is expressed on both tumor vasculature and tumor cells makes it an ideal target, since extravasation is not required to observe tumor signal. 45, 46 Synthesis and Characterization of ZnO NWs. Vapor deposition of ZnO NWs was conducted in an alumina tube placed inside a single-zone tube furnace. ZnO powder, located at the center of the tube, was used as the precursor. Cooling collars were installed on both ends of the alumina tube to create a temperature gradient for deposition control. The tube was filled with argon at a constant flow rate of 50 cm 3 /min and the deposition pressure was kept at 300 mTorr. A polycrystalline alumina substrate was located at 20 cm away from the source, where the local deposition temperature was ∼400°C. The system was heated to 1000°C during the first 26 min with a heating rate of 40°C/min, which was subsequently heated to 1400°C with a heating rate of 10°C/min. After maintaining the system at 1400°C for 2 h, the furnace was turned off and the growth system was cooled down to room temperature (RT) naturally under the same argon atmosphere. 47 On the basis of scanning electron microscopy (SEM) and transmission electron microscopy (TEM) measurements, the assynthesized ZnO NWs were of 20À50 nm in diameter and 0.5À1 μm in length, in the form of bundles ( Figure 1a ). All NWs exhibited a curvy shape without sharp edges (Figure 1b) . Such a unique NW morphology is believed to be a result of the competition between oxidation rate and condensation rate of Zn. 47 A high condensation rate of Zn under the deposition condition provided a Zn-rich growth environment, which induced continuous nucleation for the formation of bundles of small ZnO NWs. The smooth surfaces were believed to be a result of excess Zn that could diminish the surface energy differences among different crystal facets. More importantly, the as-synthesized ZnO NWs exhibited exceptionally strong green luminescence (425À575 nm, Figure 1c ), likely due to the Zn-rich growth condition which led to a very high oxygen vacancy concentration. 48À50 The green fluorescence is clearly visible when excited with a hand-held UV lamp, even after being dispersed in ethanol at a dilute concentration (Figure 1d ).
Functionalization of ZnO NWs. Common surface-anchoring molecules for metal oxide (e.g., TiO 2 , SnO 2 , and ZnO) nanomaterials are carboxylic acids, which can form bidentate coordination bonds with one or two metal atoms. 20À22 On the basis of previous reports, herein we used 3-mercaptopropionic acid (Sigma-Aldrich) to introduce thiol groups onto the surface of ZnO NWs for further functionalization (Scheme 1). After sonicating the green fluorescent ZnO NWs to form a welldispersed suspension in ethanol, surface conjugation was carried out. Success of each reaction step was confirmed by monitoring the changes in zeta potential with a Malvern Zeta Sizer Nano (Malvern Instruments). Three milligrams of 3-mercaptopropionic acid was added to a suspension of 5 mg of ZnO NWs in 2 mL of dichloromethane (DCM). The reaction mixture was stirred at room temperature for 1 h. After evaporation of DCM, the white solid was collected and washed with ethanol three times. Two milligrams of the resulting product (denoted as "NW-SH") were then reacted with 10 mg of maleimideÀpoly(ethylene glycol)Àsuccinimidyl carboxy methyl ester (Mal-PEG-SCM; Creative PEGWorks; molecular weight of PEG: 5000) for 1 h at room temperature in 2 mL of phosphate-buffered saline (PBS, pH = 7.4), in the presence of tris(2-carboxyethyl)phosphine hydrochloride (TCEP; Sigma-Aldrich). The product (denoted as "NW-PEG") was collected by centrifugation at 8000 rpm for 5 min and washed repeatedly with ethanol and Millipore-grade water. All ZnO NW conjugates in this work were purified in the same manner.
To synthesize NW-PEG-RGD, 10 mg of Mal-PEG-SCM was reacted with 1.3 mg of the c(RGDyK) peptide, where "y" denotes D-tyrosine, in 2 mL of PBS (pH = 8.5) for 4 h at room temperature. Subsequently, the pH of the reaction mixture was adjusted to 7.0. Two milligrams of NW-SH was then added, and the reaction was allowed to proceed for 1 h at room temperature in the presence of TCEP. The purified product was denoted as "NW-PEG-RGD". Both NW-PEG and NW-PEG-RGD were resuspended in PBS (pH = 7.4) to form a stock solution of 2 mg/mL for further investigation.
The as-synthesized ZnO NW and NW-SH had zeta potentials of À29.5 ( 1.8 and À21.2 ( 2.4 mV, respectively. The zeta potentials of NW-PEG and NW-PEG-RGD were À26.1 ( 3.5 and À9.1 ( 0.9 mV, respectively. On comparison of these values, 3-mercaptopropionic acid and PEG conjugation significant changed the zeta-potential of ZnO NW, and RGD peptide conjugation caused the most pronounced difference. These observations strongly suggested successful surface conjugation of RGD peptides to the NW. To further confirm this aspect, ZnO NWs were mixed with the RGD peptide first and thoroughly washed, which had a zeta potential value of À20.1 ( 4.2 mV, significantly different from that of NW-PEG-RGD (À9.1 ( 0.9 mV). SEM studies of ZnO NWs on the wafer indicated that the morphology and/or size of ZnO NWs did not change after surface functionalization (Figure 1e ), which is expected since all reactions were carried out in either organic solvent (i.e., DCM) or neutral aqueous buffer solutions. Furthermore, there was no observable difference between the absorbance/fluorescence spectra of ZnO NW and its conjugates.
Scheme 1. The Syntheses of ZnO NW Conjugates
Fluorescence Microscopy Studies. To investigate the cancer cell targeting characteristics of functionalized ZnO NWs, taking advantage of their intrinsic fluorescence, U87MG human glioblastoma (high integrin R v β 3 expression) and MCF-7 human breast cancer (integrin R v β 3 -negative) cells were used. 9, 11 To identify the optimal concentration and incubation time, a pilot study in live U87MG cells was performed with different concentrations of NW-PEG-RGD (i.e., 5, 30, and 100 μg/mL), and fluorescence images of the cells were taken at multiple time points after incubation (i.e., 15 min, 30 min, 1 h, and 3 h) using a Nikon Eclipse Ti-E fluorescence microscope (excitation, 330À 380 nm; emission, 420 nm long pass; magnification, 200Â; exposure, 0.3 s). As can be seen in Figure 2 , the fluorescence signal on U87MG cells was substantially weaker at 5 μg/mL of NW-PEG-RGD when compared to that at 30 μg/mL. Increasing the concentration of NW-PEG-RGD to 100 μg/mL did not result in substantial improvement in terms of either the signal intensity or image quality, which may be due to saturation of integrin R v β 3 proteins on the cell surface.
On comparison of the various time points, incubation for 1 h resulted in the strongest fluorescence intensity on U87MG cells, while 15 and 30 min of incubation appeared to be not sufficient for maximum integrin R v β 3 binding of NW-PEG-RGD. Most of the fluorescence signal was at the cell surface since integrin R v β 3 is a membrane-bound receptor. The fluorescence signal was substantially lower at 3 h when compared to 1 h postincubation, likely due to dissolution of ZnO NWs after receptor-mediated endocytosis (endosomes are acidic with a pH around 5 which can dissolve ZnO NWs). Taken together, a concentration of 30 μg/mL and an incubation period of 1 h gave the best imaging results, which was adopted for further studies to confirm the integrin R v β 3 specificity of NW-PEG-RGD.
Cell Staining of NW-PEG-RGD Is Integrin r v β 3 -Specific. Cold acetone-fixed U87MG and MCF-7 cells were stained with 30 μg/mL of NW, NW-PEG, NW-PEG-RGD, or NW-PEG-RGD in the presence of 2 μM of c(RGDyK) (i.e., blocking), in a binding buffer (pH 7.4). 9 One hour later, the cells were washed with cold PBS three times and examined under a microscope. For MCF-7 cells which express very low level of integrin R v β 3 on the cell surface, little to no fluorescence signal of NW, NW-PEG, or NW-PEG-RGD was observed (Figure 3) . For U87MG cells which express high level of integrin R v β 3 , intense fluorescence signal was observed for NW-PEG-RGD but not for NW or NW-PEG. Blocking with the c(RGDyK) peptide resulted in substantially lower fluorescence signal in U87MG cells, which confirmed the high affinity and integrin R v β 3 -specific binding of NW-PEG-RGD. Taken together, these cell-based studies demonstrated that NW-PEG-RGD can specifically recognize integrin R v β 3 on cell surface with minimal nonspecific binding. In addition, there is minimal nonspecific binding of NW and NW-PEG to U87MG and MCF-7 cells.
Such promising in vitro findings warrant further investigation of ZnO NWs for in vivo applications, where they may serve as a nanoplatform for image-guided tumor vasculature-targeted drug delivery. For optical imaging in vivo, fluorescence emission in the near-infrared (NIR 700À900 nm) region is preferred. 6 Doping with Ce 51 or Eu 52 may be investigated in the future to achieve red-to-NIR luminescence of ZnO NWs. Optical imaging, which takes advantage of its intrinsic fluorescence, can provide convenient tracking of ZnO NW conjugates in small animal models. Furthermore, the intrinsic fluorescence of ZnO NWs can enable microscopy/histology studies without an exogenous dye, which can serve as a convenient and robust means for validating in vivo results.
An alternative and complementary approach to study ZnO NW distribution in vivo is via radionuclide-based imaging techniques, such as positron emission tomography (PET). 53, 54 Attaching PET isotopes to ZnO NW conjugates is highly beneficial since PET is very sensitive (down to 10 À12 molar), quantitative, and clinically relevant with superb tissue penetration. 55 One scenario where Nano Letters LETTER such a dual-modality PET/optical agent is particularly useful is that an initial whole-body PET scan can be carried out to identify the location of tumor(s), and optical imaging can be subsequently used to guide tumor resection.
PET Imaging with 64 Cu-Labeled ZnO NWs. As a proof-ofprinciple pilot study, we labeled ZnO NWs with 64 Cu (t 1/2 , 12.7 h) and evaluated the biodistribution with PET in three 6-week-old female Balb/c mice. The macrocyclic chelator DOTA (1,4,-7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) has been widely used for 64 Cu-labeling and PET imaging.
56À58 To synthesize NW-PEG-DOTA, 10 mg of Mal-PEG-NH 2 (molecular weight of PEG: 5000) was mixed with 1.5 mg of DOTA-Nhydroxysuccinimide (NHS) ester in 2 mL of PBS (pH ∼ 8.5) for 4 h at room temperature. Subsequently, the pH of the reaction mixture was adjusted to 7.0. Two milligrams of NW-SH was added, and the reaction was allowed to proceed for 1 h at room temperature in the presence of TCEP. The product, NW-PEG-DOTA, was purified and resuspended in PBS.
For 64 Cu-labeling, 111 MBq of 64 CuCl 2 was diluted in 300 μL of 0.1 M sodium acetate buffer (pH ∼6.5) and added to 200 μg of NW-PEG-DOTA. The reaction mixture was incubated for 30 min at 40°C with constant shaking. NW-PEG-DOTA- 64 Cu was then purified and reconstituted in PBS. The decay-corrected radiolabeling yield was ∼85%. Mice were each injected intravenously with 5À10 MBq of NW-PEG-DOTA- 64 Cu and scanned in a microPET/microCT Inveon rodent model scanner (Siemens Medical Solutions USA, Inc.). All animal studies were conducted under a protocol approved by the University of Wisconsin Institutional Animal Care and Use Committee. Ten-minute static PET scans, reconstructed using a two-dimensional filtered back-projection algorithm with no attenuation/ scatter correction, 59 were performed at 20 min and 20 h postinjection to noninvasively examine the biodistribution of NW-PEG-DOTA- 64 Cu. Similar to most nanomaterials, nontargeted ZnO NWs primarily accumulated in the liver (Figure 4) , the major organ of the reticuloendothelial system (RES).
60À63
Cytotoxicity of ZnO NW Conjugates. Cytotoxicity of ZnO NW and its conjugates was examined in both U87MG and MCF-7 cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, similar to that described previously. 63, 64 Cells were seeded at a density of 1. At a concentration of 30 μg/mL, the toxicity of NW-PEG-RGD and NW-PEG was low and amenable for cellular imaging ( Figure 5 ). Overall, PEG conjugation reduced the toxicity of ZnO NW in both U87MG and MCF-7 cells. The toxicity of NW-PEG-RGD was higher than that of NW and NW-PEG in U87MG cells at concentrations >20 μg/mL. Since U87MG cells express a high level of integrin R v β 3 , which is critical for cell adhesion to the wells, a high concentration of RGD peptides on ZnO NWs likely contributed to its cellular toxicity. In addition, NW-PEG-RGD can be internalized into U87MG cells (through receptormediated endocytosis) more readily than NW/NW-PEG and dissolve in the endosome and/or lysosome. The high intracellular concentration of Zn 2+ may also have caused the enhanced toxicity of NW-PEG-RGD in U87MG cells. On the other hand, the toxicity of NW-PEG-RGD was lower than that of NW and similar to that of NW-PEG in MCF-7 cells. Since MCF-7 cells do not express significant level of integrin R v β 3 , high concentrations of RGD peptides on ZnO NWs did not have significant impact on the cellular toxicity.
Many studies have focused on the biocompatibility of ZnO nanomaterials without surface modification. Although some reports showed that ZnO nanomaterials were toxic above certain concentrations, 65À67 which could be attributed to the dissolved Zn 2+ in the culture medium or inside cells, others have demonstrated that ZnO nanomaterials were nontoxic, 68 selectively toxic to bacteria or cancer cells, 33, 69 or useful as adhesion-resistant biomaterials. 70 It has been shown that the safety of ZnO nanoparticles could be improved by decreasing ZnO dissolution through Fe doping or surface capping. 71, 72 For biomedical applications of nanomaterials, surface modification is crucial. The versatile chemistry of ZnO nanomaterials can enable facile conjugation of various biocompatible polymers, imaging labels, drugs, among others. The key question is not how toxic "naked" ZnO nanomaterials are, but how to functionalize them so that they do not exhibit significant toxicity and thereby can be used in biological systems.
In conclusion, herein we demonstrated for the first time that intrinsically fluorescent ZnO NWs can be employed for cancertargeted optical imaging, upon surface functionalization to render water solubility, biocompatibility, and low cellular toxicity. Much ' REFERENCES
